<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-1784581243399/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T21:10:25.516Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças não recebem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-1784581242692/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T21:01:21.189Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir remédio contra HIV: novo passo</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/lei-cria-politica-fortalecer-industria-saude/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T19:10:09.198Z</news:publication_date>
      <news:title>Lei cria política para fortalecer indústria da saúde e reduzir dependência externa</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-1784573462215/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T19:01:06.076Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV: entenda</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-1784573462564/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T18:51:40.184Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças não recebem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-1784565652730/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T17:10:02.997Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças sem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-1784565651896/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T16:50:21.602Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sinais-cancer-colorretal-devem-ser-checados-rapidez-saiba-mais/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T16:50:21.602Z</news:publication_date>
      <news:title>Sinais do câncer colorretal: alerta para checagem rápida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/anvisa-aprova-novo-medicamento-linfoma-nao-hodgkin/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T16:41:26.906Z</news:publication_date>
      <news:title>Anvisa aprova novo medicamento para linfoma não Hodgkin: Columvi</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/alimentacao/13-alimentos-que-regulam-o-ph-do-corpo-lista-completa/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T16:07:55.192Z</news:publication_date>
      <news:title>13 alimentos que regulam o pH do corpo (lista completa)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-1784557850016/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T14:50:37.975Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-1784557850568/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T14:40:02.719Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças não recebem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-1784550052662/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T12:30:16.099Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças não recebem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-1784550052165/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T12:30:16.099Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/bem-estar/guia-completo-para-desintoxicar-o-corpo-naturalmente/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T12:08:02.018Z</news:publication_date>
      <news:title>Guia completo para desintoxicar o corpo naturalmente</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/alimentacao/reduzir-acucar-cafe-5-passos-sem-sofrimento/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T11:22:46.364Z</news:publication_date>
      <news:title>Reduzir açúcar café: 5 passos sem sofrimento</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-1784542245525/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T11:00:38.903Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças sem vacina no 1° ano de vida em 2025</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-1784542245127/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T11:00:38.903Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-1784534439635/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T11:00:38.903Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças sem vacina no 1° ano em 2025</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-1784534439205/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T11:00:38.903Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/bem-estar/9-sinais-de-deficiencia-de-magnesio-que-voce-ignora-sintomas/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:52:42.352Z</news:publication_date>
      <news:title>9 Sinais de Deficiencia de Magnesio que Voce Ignora - Sintomas</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-34/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:50:09.856Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças não recebem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-1784526635987/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:40:28.315Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças sem vacina no 1° ano de vida em 2025</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-41/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:30:03.762Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças sem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-27/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:30:03.762Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-41/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:20:02.915Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-35/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:20:02.915Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças sem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-1784518833708/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:11:08.772Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-43/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:11:08.772Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-50/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:00:21.736Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV na Fiocruz</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-35/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T10:00:21.736Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-43/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:40:24.909Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças não recebem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-39/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:40:24.909Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV: Fiocruz assume produção do dolutegravir</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-38/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:40:24.909Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-45/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:30:02.871Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-47/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:20:26.512Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-42/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:20:26.512Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-32/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:20:26.512Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças sem vacina no 1° ano de vida em 2025</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-44/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:10:26.276Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-39/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:10:26.276Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças não recebem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-34/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:10:26.276Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-30/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:10:26.276Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças não recebem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-1784526635599/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T09:00:25.832Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-32/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T08:50:07.104Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-29/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T08:50:07.104Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-49/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T08:30:03.938Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças não recebem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-33/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T08:30:03.938Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/sus-adquire-tecnologia-produzir-principal-remedio-contra-hiv-30/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T08:30:03.938Z</news:publication_date>
      <news:title>SUS adquire tecnologia para produzir principal remédio contra o HIV: entenda</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-42/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T08:20:03.937Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças sem vacina no 1° ano de vida</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://revistaaptare.com.br/prevencao/unicef-135-milhoes-criancas-nao-recebem-vacina-1-ano-vida-37/</loc>
    <news:news>
      <news:publication>
        <news:name>Aptare</news:name>
        <news:language>pt</news:language>
      </news:publication>
      <news:publication_date>2026-07-20T08:10:04.088Z</news:publication_date>
      <news:title>Unicef: 13,5 milhões de crianças sem vacina no 1° ano de vida em 2025</news:title>
    </news:news>
  </url>
</urlset>